Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00834795 · ClinicalTrials.gov registry record · Phase 1
Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00834795: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00834795 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00834795, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The objective of this randomized, single-dose, two-way crossover evaluation is to compare the relative bioequivalence of a test carvedilol formulation (TEVA Pharmaceuticals USA) to and equivalent oral dose of the commercially available carvedilol (COREG®, SmithKline Beecham Pharmaceuticals) in a test population of 36 adult individuals under fasting conditions.
Interventions
- DRUG Carvedilol 25 mg tablets
- DRUG COREG® 25 mg tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2001-12 |
| Est. Completion | 2001-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00834795
The ClinicalTrials.gov registry entry for NCT00834795 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carvedilol 25 mg tablets is the first listed.
NCT00834795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00834795 about?
NCT00834795 is a clinical study titled "Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects". The objective of this randomized, single-dose, two-way crossover evaluation is to compare the relative bioequivalence of a test carvedilol formulation (TEVA Pharmaceuticals USA) to and equivalent oral dose of the commercially available carvedilol (COREG®, SmithKline Beecham Pharmaceuticals) in a tes...
What is the current status of trial NCT00834795?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2001-12. Estimated completion is 2001-12.
What interventions are being tested in trial NCT00834795?
The interventions under investigation include: Carvedilol 25 mg tablets (DRUG), COREG® 25 mg tablets (DRUG).
Who is sponsoring clinical trial NCT00834795?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.